Open an account

Incannex Healthcare

IXHL · NASDAQ

$2.64+$0.04 (+1.54%)TodayMarket closed ·
Prev close $2.60

About IXHL

Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. The firm is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.

Employees
12
Headquarters
New York City, New South Wales
Listed
Mar 18, 2022
Sector
Health Care
Industry
Pharmaceuticals
Website
incannex.com

IXHL key statistics

Market cap
33.12M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
63.29K
Volume
40.26K
Open price
$2.60
High today
$2.69
Low today
$2.57
52 Week high
$14.91
52 Week low
$2.49

Incannex Healthcare (IXHL) at a glance

Incannex Healthcare (IXHL) last traded at $2.64, with a market cap of 33.12M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.57 and $2.69. The current price is 2.7% above the day's low and 1.9% below its high.

Volume so far is 40.26K shares, below the average of 63.29K shares a day.

Over the past year Incannex Healthcare has ranged from $2.49 to $14.91, and now sits 1% of the way up that range.

Incannex Healthcare met or beat analyst EPS estimates in 1 of the last 8 quarters. In Q4 FY26 it reported -$4.93 per share against an estimate of -$0.762.

The average analyst price target is $18.98, 619.0% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 4 analystsAvg $18.98
Low
$18.18
Now
$2.64
High
$20.18

IXHL earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 8 quarters, by 82.9% on average.

  1. Q1 FY25: reported -$324.84 per share against an estimate of -$22.36
  2. Q2 FY25: reported -$287.67 per share against an estimate of -$20.68
  3. Q3 FY25: reported -$238.98 per share against an estimate of -$22.16
  4. Q4 FY25: reported -$15.30 per share against an estimate of -$89.29
  5. Q1 FY26: reported -$22.95 per share against an estimate of -$0.9449
  6. Q2 FY26: reported -$22.83 per share against an estimate of -$0.9449
  7. Q3 FY26: reported -$11.23 per share against an estimate of -$0.9449
  8. Q4 FY26: reported -$4.93 per share against an estimate of -$0.762

IXHL news

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Avi Kapoor

    Crude Oil Surges Over 8%; Dollar General Shares Fall After Q4 Results

  • Avi Kapoor

    Dow Tumbles Over 1%; US Weekly Jobless Claims Fall

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Chris Katje

    EXCLUSIVE: August's 20 Most-Searched Tickers On Benzinga Pro – Where Do Opendoor, Palantir, BitMine Immersion, Apple Stock Rank?

  • Press releaseGlobe Newswire

    Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea

  • Chris Katje

    EXCLUSIVE: July's 20 Most-Searched Tickers On Benzinga Pro — Where Do Opendoor, Nvidia, Apple Stock Rank?

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.